New drug cocktail aims to stall lung cancer
NCT ID NCT07005336
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding a new drug called uliledlimab to standard immunotherapy and chemotherapy can help people with advanced non-small cell lung cancer live longer without their disease getting worse. About 150 adults who have not had prior treatment for their advanced cancer will be randomly assigned to receive either the three-drug combo or the standard two-drug combo. The trial is currently active but not recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
uliledlimab combined with sintilimab and chemotherapy
What this could lead to
If successful, this could lead to a new treatment option that slows the progression of advanced lung cancer.
What could go wrong
This is an early Phase 2 trial with only 150 participants, so results may not apply to everyone. There is also a risk of serious side effects from the combination therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Provincial Cancer Hospital
Hefei, China
-
Beijing Chest Hospital
Beijing, China
-
Binzhou Medical University Hospital
Binzhou, China
-
Chongqing University Three Gorges Hospital
Chongqing, China
-
First Hospital of Shanxi Medical University
Taiyuan, China
-
General Hospital of Ningxia Medical University
Yinchuan, China
-
Guangxi Medical University Cancer Hospital
Nanning, China
-
Harbin Medical University Cancer Hospital
Ha’erbin, China
-
Hubei Cancer Hospital
Wuhan, China
-
Jiangmen Central Hospital
Jiangmen, China
-
Linyi People's Hospital
Linyi, China
-
Lishui Central Hospital
Lishui, China
-
Shanghai Chest Hospital
Shanghai, China
-
Shanxi Provincial Cancer Hospital
Taiyuan, China
-
Sichuan Cancer Hospital
Chengdu, China
-
The First Affiliated Hospital of Anhui Medical University
Hefei, China
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, China
-
The First Affiliated Hospital of Nanchang University
Nanchang, China
-
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
-
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
-
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
-
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
-
The Second People's Hospital of Neijiang
Neijiang, China
-
The Second People's Hospital of Yibin
Yibin, China
-
Xiangyang Central Hospital
Xiangyang, China
-
Yunan Cancer Hospital
Kunming, China
-
Zhoukou Central Hospital
Zhoukou, China